from Phase 3 clinical trials showed the vaccine to be safe, and able to reduce moderate to severe outcomes from Covid-19 by about 72 percent in the U.S.A health care worker holds vials containing doses of the Johnson & Johnson Covid-19 vaccine as South Africa proceeds with its inoculation campaign at the Klerksdorp Hospital on Feb. 18, 2021.Among the study participants in South Africa, where a new variant has been spreading, efficacy was found to be 64 percent for moderate to severe disease.
Panel member Dr. Eric Rubin wondered what would happen if a two-dose formulation ultimately proves to be superior. "You can see where that would be confusing to people where they may be thinking, 'Maybe I didn’t get what I need?'"
Nichole has gotten very boring now that Trump isn't the lead story 24/7.
Ship them to Tennessee!
Serious game changer. 🎊🎊🎊
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.